Univest
Univest
  • Markets

Syngene Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review

  • June 9, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Syngene Stock Prediction 2026

Syngene CMP: Rs 452 (2026). 52W High: Rs 729. 52W Low: Rs 380. Mkt Cap: Rs 18,337 Cr. P/E: 50.8. Analyst Consensus Target: Rs 505.

The Syngene stock predictions for 2026 from leading brokerages and research analysts span a wide range, reflecting the company’s sector dynamics, earnings trajectory, and macro environment. The Syngene stock prediction published in this article is sourced from publicly available research and may or may not be achieved. Investors should treat any Syngene share price prediction as one data point and not as a guarantee of future performance.

Interest in the Syngene stock forecast for 2026 has grown as investors look for anchor points in a volatile market. This article reviews every dimension of the Syngene stock prediction that analysts are tracking, including key business drivers, bull and bear scenarios and the primary risks that could shift the Syngene share price prediction in either direction. The analyst consensus for 2026 should be verified with the latest brokerage reports before any investment decision.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Analysts Predict for Syngene Stock in 2026
  • Syngene Company Overview
  • Syngene Stock Prediction by Time Horizon
    • Short-Term Syngene Stock Prediction (1 to 3 Months)
    • 12-Month Syngene Stock Prediction
    • Long-Term Syngene Stock Prediction
  • Syngene Stock Forecast: Key Factors Behind the Prediction
    • US Generic Revenue
    • Domestic Formulations Growth
    • R&D Pipeline
    • EBITDA Margin
  • Syngene Stock Prediction: Bull and Bear Scenarios
  • How Analysts Are Reading the Syngene Stock Story
  • Key Risks That Could Change the Syngene Stock Prediction
    • USFDA Regulatory Risk
    • Price Erosion in the US
    • R&D Execution Risk
    • Currency Risk
  • How to Monitor the Syngene Stock Forecast and Make Decisions
  • Conclusion
  • Frequently Asked Questions on Syngene Stock Prediction 2026
    • What is the Syngene stock prediction for 2026?
    • Is the Syngene stock prediction bullish or bearish?
    • What is the Syngene share price prediction based on fundamentals?
    • What is the long-term Syngene stock prediction?
    • What are the key risks to the Syngene stock prediction?
    • What does the Syngene stock forecast say for 2026?
    • Where can I track the latest Syngene stock prediction?

What Analysts Predict for Syngene Stock in 2026

Analyst consensus on the Syngene stock prediction for 2026 is tracked by leading brokerages and research firms. The table below shows the latest available Syngene stock forecast data from JM Financial and ICICI Securities. All Syngene share price prediction figures are sourced from publicly available research and should be verified against the most current brokerage reports before publishing.

Brokerage Rating Syngene Stock Prediction (Rs) Updated
JM Financial Buy Rs 530 2026
ICICI Securities Neutral Rs 480 2026
Analyst Consensus — Rs 505 2026

The Syngene stock prediction range from the analyst community reflects a genuine difference of opinion on demand recovery, margin trajectory and sector headwinds. Each Syngene share price prediction from an individual brokerage should be read alongside the stated assumptions. The implied upside in the Syngene stock forecast from the current market price of Rs 452 may or may not be realised by the end of 2026.

3 Stocks Building Serious Momentum Right Now

When Univest analysts identify high-conviction stock opportunities, investors pay attention.

Our research team has now shortlisted the Top Stocks to Buy based on current market momentum, sector trends & growth potential for 2026.

  • Discover stocks investors are actively accumulating
  • High-conviction opportunities backed by research
  • Designed for the next phase of market growth

Unlock the latest Top Stock Picks now on Univest

See the Stocks →

Syngene Company Overview

Syngene International is a significant player in India’s pharmaceutical industry with a presence across domestic formulations, US generics and specialty segments. The Syngene stock prediction for 2026 reflects both the pipeline growth potential and regulatory risk. Understanding this context is the starting point for any Syngene stock prediction and helps investors assess whether the analyst Syngene stock forecast is grounded in a realistic view of the company’s competitive position.

Metric Value
NSE Ticker SYNGENE
Sector Pharmaceuticals and Healthcare
CMP Rs 452 (2026)
52 Week High Rs 729
52 Week Low Rs 380
Market Cap Rs 18,337 Cr
P/E Ratio 50.8
Syngene Stock Prediction Consensus (12M) Rs 505

Syngene Stock Prediction by Time Horizon

Analysts split the Syngene share price prediction across different time frames because the variables that drive the short-term view are very different from those that shape a 3 to 5 year outlook. The following three horizons give a structured way to think about the range of analyst estimates for 2026 and beyond.

Short-Term Syngene Stock Prediction (1 to 3 Months)

The near-term analyst view on Syngene International reflects current market sentiment, sector news flow and upcoming earnings data points. Analysts forming a short-term Syngene stock forecast are watching key support and resistance levels around the current market price of Rs 452. A Syngene share price prediction in the near term is the most uncertain of all time horizons and may or may not hold as new information emerges.

12-Month Syngene Stock Prediction

The 12 month Syngene stock prediction from leading brokerages represents the most widely cited analyst consensus for the full-year 2026 outlook. JM Financial has set a target of Rs 530 (Buy) while ICICI Securities has set a target of Rs 480 (Neutral). Most research desks refresh their Syngene stock forecast within two to four weeks of each quarterly earnings print. The Syngene share price prediction should be verified against the most recent analyst reports before being used as an investment reference.

Long-Term Syngene Stock Prediction

The long-term Syngene stock prediction, built on a 3 to 5 year view, is based on assumptions about demand recovery, margin expansion and revenue diversification. Analysts who set a higher long-term Syngene stock forecast cite the company’s structural growth drivers in the Pharmaceuticals and Healthcare sector. The long-term Syngene share price prediction should be treated as a directional indicator and may or may not prove accurate over the forecast period.

Syngene Stock Forecast: Key Factors Behind the Prediction

Understanding what drives the Syngene stock forecast requires reviewing the variables that most analysts reference when forming their Syngene share price prediction for 2026. The following four factors appear consistently in research reports on the Syngene stock prediction and are the primary inputs into the bull and bear case scenarios.

US Generic Revenue

US generics revenue is the most watched metric in the Syngene stock forecast. USFDA approval timelines and price erosion rates directly affect the Syngene share price prediction from most research desks.

Domestic Formulations Growth

Domestic formulation growth provides a stable base that supports the Syngene stock prediction even when export growth faces headwinds.

R&D Pipeline

The depth and commercialization pace of the R&D pipeline is a key variable in the long-term Syngene share price prediction. New product approvals are cited as catalysts for the Syngene stock prediction.

EBITDA Margin

Sustained EBITDA margin expansion is typically the basis for the bullish Syngene stock forecast. Margin recovery strengthens the Syngene share price prediction from most research desks.

Syngene Stock Prediction: Bull and Bear Scenarios

Any complete Syngene share price prediction must account for both positive and negative outcomes. The following scenarios are built from analyst commentary and sector data, representing the range of the Syngene stock prediction rather than a fresh estimate from Univest.

Scenario Syngene Stock Prediction Key Conditions
Bull Case Rs 530 Strong business execution, margin improvement, favourable macro environment and sector re-rating
Base Case Rs 505 Steady performance, gradual recovery, margins hold, growth on track
Bear Case Rs 380 Demand deterioration, margin pressure, sector de-rating and macro headwinds

The bull case Syngene stock forecast assumes most positive variables converge simultaneously. The bear case Syngene share price prediction reflects a scenario where demand deteriorates and the sector de-rates below current multiples. The base case Syngene stock prediction represents the analyst consensus view of Rs 505, which may or may not prove accurate.

How Analysts Are Reading the Syngene Stock Story

Analyst reviews of the Syngene share price prediction consistently highlight two opposing forces in 2026. The positive case for the Syngene stock forecast rests on the company’s core business strengths in the Pharmaceuticals and Healthcare sector, including competitive position and potential for margin or volume improvement over the next four quarters.

The cautious side of the analyst view points to near-term headwinds from macro uncertainty, competitive pressure and sector-level challenges. Analysts who maintain a conservative Syngene stock prediction cite these as the primary reasons for staying neutral or cautious on the stock. Many research desks have revised their view since the start of 2026 as macro data evolved.

Overall, the Syngene stock prediction consensus from the analyst community is built on real business strengths set against real risks. Investors should read the full Syngene stock forecast report from each brokerage, including assumptions and risk disclosures, before using any Syngene share price prediction as an investment reference.

Key Risks That Could Change the Syngene Stock Prediction

Any Syngene share price prediction carries risks that could shift the Syngene stock forecast materially in either direction. Investors should review these risks before acting on any Syngene stock prediction from an analyst or research desk.

USFDA Regulatory Risk

Import alerts and warning letters from the USFDA are the most significant risks to the Syngene stock prediction. A facility closure would force an immediate sharp revision to the Syngene share price prediction.

Price Erosion in the US

Pricing pressure in US generics compresses the revenue per product and affects the Syngene stock forecast. Aggressive price erosion pushes the Syngene share price prediction toward the bear case.

R&D Execution Risk

Delays in clinical trials or approval failures affect the Syngene stock prediction. The Syngene share price prediction is particularly sensitive to key pipeline asset announcements.

Currency Risk

A strengthening rupee against the dollar reduces export realisation and affects the Syngene stock forecast. Currency risk is embedded in conservative Syngene share price prediction models.

How to Monitor the Syngene Stock Forecast and Make Decisions

Check Live Syngene Fundamentals on the Univest Screener

Start by opening a demat account with a SEBI registered broker if you do not already have one. Before acting on any Syngene share price prediction, ensure you understand the risks involved in equity investing.

Track the Syngene stock prediction consensus quarterly: after every earnings release, most brokerages revise their Syngene stock forecast within two weeks. Comparing the revised Syngene stock prediction to the previous estimate tells you whether analyst sentiment on the stock is improving or deteriorating.

Compare the current market price of Rs 452 with the analyst target range of Rs 530 to Rs 480. The Syngene share price prediction band can be wide, so position size should reflect that uncertainty.

Review the Syngene stock prediction every quarter against the key business metrics for the Pharmaceuticals and Healthcare sector. A single estimate from any analyst is a point-in-time view and should be treated as one input among many.

Download the Univest iOS App or Univest Android App to track the live Syngene stock prediction and Syngene share price prediction changes in real time.

Conclusion

The Syngene stock prediction for 2026 reflects the analyst community’s assessment of Syngene International’s competitive position, earnings trajectory and macro environment. JM Financial sets a Buy target of Rs 530 while ICICI Securities has a Neutral target of Rs 480, giving an analyst consensus of Rs 505. The Syngene stock forecast is set against near-term risks that make the Syngene share price prediction range wide. Any estimate should be verified with the latest brokerage reports and does not constitute investment advice from Univest.

The analyst forecast will be revised after every quarterly result. Track the latest Syngene stock prediction and Syngene share price prediction changes on the Univest Screener and app to stay updated as 2026 progresses.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

Disclaimer: Data and figures in this article are sourced from publicly available information on Google and other public platforms. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Syngene Stock Prediction 2026

What is the Syngene stock prediction for 2026?

Ans. The Syngene stock prediction for 2026 is based on analyst consensus from leading brokerages including JM Financial and ICICI Securities. The Syngene share price prediction range reflects the company’s fundamentals, sector outlook and macro environment. All estimates are analyst views and may or may not be achieved.

Is the Syngene stock prediction bullish or bearish?

Ans. The Syngene stock prediction for 2026 is divided, with JM Financial maintaining a Buy stance with a target of Rs 530. The Syngene stock forecast consensus points to potential movement from current levels, though the Syngene share price prediction range is wide, reflecting macro uncertainty.

What is the Syngene share price prediction based on fundamentals?

Ans. The Syngene share price prediction built on fundamentals considers the US generic pipeline, domestic growth, EBITDA margin and regulatory compliance track record. Analysts tracking the Syngene stock forecast closely cite these variables as the primary drivers of the 2026 outlook. Each analyst estimate may or may not reflect actual future performance.

What is the long-term Syngene stock prediction?

Ans. The long-term Syngene stock prediction is built around the assumption that the company’s core business drivers sustain over a multi-year horizon. Analysts with a higher Syngene stock forecast point to demand recovery, margin improvement and revenue diversification. The long-term estimate carries more uncertainty than the 12-month consensus of Rs 505.

What are the key risks to the Syngene stock prediction?

Ans. The key risks to the Syngene stock prediction in 2026 include sector-specific headwinds, macro uncertainty, regulatory changes and competitive pressure. Analysts who set a lower Syngene share price prediction cite these as the primary downside risks. Every estimate should be read alongside its stated risk assumptions.

What does the Syngene stock forecast say for 2026?

Ans. The Syngene stock forecast for 2026 reflects a cautiously positive analyst consensus based on the company’s fundamental strengths. JM Financial has a Buy rating with a target of Rs 530 while ICICI Securities has a Neutral rating with a target of Rs 480. These Syngene share price prediction estimates may or may not prove accurate.

Where can I track the latest Syngene stock prediction?

Ans. You can track the latest Syngene stock prediction, live price and fundamentals on the official NSE and BSE websites and on the Univest app and screener, alongside every updated Syngene share price prediction and stock forecast from the analyst community.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply